PMGC Holdings (ELAB) Change in Accured Expenses (2023 - 2026)
PMGC Holdings (ELAB) posted Change in Accured Expenses of $116488.0 for Q1 2026, down 83.17% sequentially from $692218.0 in Q4 2025, and down 55.14% YoY from $259661.0 in Q1 2025.
PMGC Holdings (ELAB) Change in Accured Expenses (2023 - 2026) Analysis & Trends
PMGC Holdings has reported Change in Accured Expenses for 4 years, with the latest figure at $116488.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 55.14% year-over-year to $116488.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $814586.0 (up 34.01% YoY) and the FY2025 annual result came in at $957759.0, up 361.58% from the prior year.
- Change in Accured Expenses slipped to $116488.0 in Q1 2026 per ELAB's latest filing, from $692218.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $692218.0 in Q4 2025 and troughed at -$428929.0 in Q2 2025.
- A 4-year average of $134510.4 and a median of $130484.0 in 2023 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses sank 1097.29% in 2024, then jumped 494.15% in 2025.
- Over 4 years, Change in Accured Expenses stood at $17610.0 in 2023, then tumbled by 1097.29% to -$175622.0 in 2024, then surged by 494.15% to $692218.0 in 2025, then plunged by 83.17% to $116488.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $116488.0, $692218.0, and $434809.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | 965,076.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116,488.00 |
| Mar 31, 2026 | 116,488.00 |
| Dec 31, 2025 | 692,218.00 |
| Dec 31, 2025 | 692,218.00 |
| Sep 30, 2025 | 434,809.00 |
| Sep 30, 2025 | 434,809.00 |
| Jun 30, 2025 | -428,929.00 |
| Jun 30, 2025 | -428,929.00 |
| Mar 31, 2025 | 259,661.00 |
| Mar 31, 2025 | 259,661.00 |
| Dec 31, 2024 | -175,622.00 |
| Dec 31, 2024 | -175,622.00 |
| Sep 30, 2024 | 173,008.00 |
| Sep 30, 2024 | 173,008.00 |
| Jun 30, 2024 | 350,809.00 |
| Jun 30, 2024 | 350,809.00 |
| Mar 31, 2024 | -140,698.00 |
| Mar 31, 2024 | -140,698.00 |
| Dec 31, 2023 | 17,610.00 |
| Dec 31, 2023 | 17,610.00 |